Venus Remedies Ltd

The financial performance and growth of Venus Remedies Ltd. present a mixed trend. The compounded sales growth over 5 years is 14%, indicating a positive trajectory in revenue. However, the compounded profit growth over 3 years is -1%, suggesting challenges in maintaining profitability. Quarterly sales have been volatile, with YOY sales growth fluctuating significantly. The OPM% has also varied, indicating inconsistency in operational efficiency. While sales have grown, the ability to translate this into consistent profit remains a concern.

| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 | |---|---|---|---|---|---| | Compounded Sales Growth | N/A | N/A | N/A | N/A | N/A | 9% | | Compounded Profit Growth | N/A | N/A | N/A | N/A | N/A | 39% |

Venus Remedies Ltd.'s capital efficiency and returns present a mixed performance. The ROCE has improved to 11% in Mar 2025, indicating better utilization of capital. However, the ROE remains at 6.18%, which is relatively low. Cash Conversion Cycle has improved to 72 Days in Mar 2025, suggesting enhanced working capital management. Overall, while there are improvements in some areas, the returns on equity need enhancement.

| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 | |---|---|---|---|---|---| | ROCE % | 5% | 1% | 8% | 8% | 9% | 11% |

The financial health and prudence of Venus Remedies Ltd. show positive trends. The company has significantly reduced its borrowings over the years. The interest coverage ratio is strong as interest expenses are zero in recent years. The company has not been paying dividends. The debt-to-equity ratio suggests a manageable leverage position.

| Metric | 2014-2016 | 2017-2019 | 2020-2022 | 2023 | 2024 | 2025 | |---|---|---|---|---|---| | Borrowings | 318.33 | 305.67 | 45.67 | 42 | 41 | 2 |

The shareholding and ownership structure of Venus Remedies Ltd. indicate stability. The promoter holding has been consistently around 41.76%, suggesting confidence in the company. FII holding has increased slightly over the past few years, indicating growing interest from foreign institutional investors.

There is no specific data available on off-balance sheet exposure quantification.

There is no specific data available on contingent liability evaluation.

There is no specific data available on segment performance volatility.

There is no specific data available on foreign exchange or interest rate exposure.

There is no specific data available on regulatory compliance cost trends.